May 17, 2020

Rimidi and Eli Lilly partner up to develop a new diabetes platform

diabetes
Catherine Sturman
2 min
diabetes management
A leading provider in bringing personalised, diabetes management solutions to the market, digital health company Rimidi is set to partner with Eli Lily...

A leading provider in bringing personalised, diabetes management solutions to the market, digital health company Rimidi is set to partner with Eli Lily and Company to create new, provider-focused tools and integrated, tailored solutions for diabetics who use insulin throughout their regular diabetes management.

Through the partnership, Rimidi will integrate its diabetes management software platform with Lilly's integrated insulin management system to provide an easy-to-use management system for approximately 30 million US citizens with diabetes, alongside 425 million adults worldwide. Health care providers who support the use of insulin within diabetes management and normal clinical workflows will also be supported throughout this new collaboration.

At present, Rimidi’s software solution Diabetes+Me remains focused on empowering quality diabetes care for healthcare organisations, providers, and people living with diabetes.

"Diabetes management is a collaborative effort between people with diabetes and their healthcare providers. With the right support they can achieve better results together," said Lucienne Ide, MD, PhD and CEO of Rimidi.

"We are proud to partner with Lilly to facilitate personalised management of diabetes. This is a 'better together' story."

Related stories

Rimidi's platform helps clinicians personalise care by leveraging the individual characteristics and clinical histories of people with diabetes to identify individuals who may benefit from specific management approaches. 

Lilly's integrated insulin management system, however, combines a connected insulin pen with glucose-sensing technologies (e.g., glucose meter) and software applications to deliver personalised insulin dose recommendations. Data from these devices and apps will then flow back to physicians to truly connect care.

"To make diabetes management easier, we need to enable and empower people with diabetes to use insulin more effectively," commented Marie Schiller, Vice President, Connected Care and site head, Cambridge Innovation Center.

"Our partnership with Rimidi is one step in making this vision a reality. Diabetes is a challenge for patients and can be tough for physicians to treat. Connected care may be able to reduce many of these burdens, allowing physicians to focus on the most important clinical decisions and improving outcomes."

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article